

Jennifer L Guerriero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403171/publications.pdf>

Version: 2024-02-01

46
papers

3,800
citations

201674

27
h-index

302126

39
g-index

49
all docs

49
docs citations

49
times ranked

9093
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 722-737.	9.4	433
2	Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. <i>Nature</i> , 2017, 543, 428-432.	27.8	423
3	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	28.9	334
4	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	16.8	263
5	Macrophages: The Road Less Traveled, Changing Anticancer Therapy. <i>Trends in Molecular Medicine</i> , 2018, 24, 472-489.	6.7	219
6	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	13.2	209
7	Genomic evolution and chemoresistance in germ-cell tumours. <i>Nature</i> , 2016, 540, 114-118.	27.8	139
8	Macrophages. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 73-93.	3.2	135
9	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	9.4	132
10	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	13.2	126
11	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. <i>Cancer Research</i> , 2016, 76, 6495-6506.	0.9	105
12	Design, Synthesis, and Biological Evaluation of New-Generation Taxoids. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3203-3221.	6.4	95
13	The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2021, 9, 8-19.	3.4	95
14	The class IA phosphatidylinositol 3-kinase p110- β subunit is a positive regulator of autophagy. <i>Journal of Cell Biology</i> , 2010, 191, 827-843.	5.2	82
15	Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 643771.	4.8	80
16	DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity. <i>Journal of Immunology</i> , 2011, 186, 3517-3526.	0.8	79
17	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	7.0	76
18	Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing. <i>Cell Reports</i> , 2020, 33, 108566.	6.4	75

#	ARTICLE	IF	CITATIONS
19	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1454-1463.	4.1	70
20	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
21	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	4.8	68
22	Apoptosis and Necrosis in the Ischemic Zone Adjacent to Third Degree Burns. <i>Academic Emergency Medicine</i> , 2008, 15, 549-554.	1.8	59
23	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx [®] Digital Spatial Profiler. <i>Cancers</i> , 2021, 13, 4456.	3.7	50
24	Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma. <i>PLoS ONE</i> , 2011, 6, e19096.	2.5	49
25	Chemotherapy Induces Tumor Clearance Independent of Apoptosis. <i>Cancer Research</i> , 2008, 68, 9595-9600.	0.9	48
26	High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. <i>Science Signaling</i> , 2020, 13, .	3.6	44
27	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021, 7, .	10.3	38
28	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2281-2293.	3.4	29
29	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	7.0	29
30	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	7.0	29
31	Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. , 2019, 7, 199.		27
32	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
33	Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates. <i>Journal of the National Cancer Institute</i> , 2022, 114, 68-77.	6.3	17
34	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 83.	5.0	13
35	Family-Centered Care for Children and Families Impacted by Neonatal Seizures: Advice From Parents. <i>Pediatric Neurology</i> , 2021, 124, 26-32.	2.1	9
36	Non-apoptotic routes to defeat cancer. <i>Oncolmmunology</i> , 2012, 1, 94-96.	4.6	7

#	ARTICLE	IF	CITATIONS
37	The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax. <i>Blood</i> , 2018, 132, 4393-4393.	1.4	7
38	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	2.4	5
39	MCL1 and DEDD Promote Urothelial Carcinoma Progression. <i>Molecular Cancer Research</i> , 2019, 17, 1294-1304.	3.4	4
40	Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer. <i>Cancer Research</i> , 2022, 82, P1-04-05-P1-04-05.	0.9	2
41	Supporting the next generation of scientists to lead cancer immunology research. <i>Cancer Immunology Research</i> , 2021, 9, canimm.0519.2021.	3.4	1
42	Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-14-18-P2-14-18.	0.9	1
43	Abstract P4-04-06: Integrative analysis of single-cell transcriptomic and spatial profiles characterized distinct tumor microenvironment phenotypes in hormone receptor positive (HR+) breast cancer. <i>Cancer Research</i> , 2022, 82, P4-04-06-P4-04-06.	0.9	1
44	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e27.	0.4	0
45	Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer. <i>Cancer Research</i> , 2022, 82, P2-07-03-P2-07-03.	0.9	0
46	Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-07-13-P2-07-13.	0.9	0